丁苯酞注射液治疗急性脑梗死的初步探讨

目的：评价丁苯酞（NBP）注射液对急性脑梗死的疗效及药物不良反应。方法选择2012年9月至2013年11月陕西省人民医院70例急性脑梗死住院患者，随机分为治疗组（n＝35）和对照组（n＝35），对照组仅予常规治疗，治疗组在常规治疗的基础上给予NBP注射液治疗。于治疗前及治疗后14d进行神经功能缺损程度评定美国国立卫生研究院卒中量表（NIHSS）和日常生活自理能力评定Barthel指数（BI）和改良Rankin量表（mRS）]并记录不良反应。90d随访时再次评定BI和mRS。结果与治疗前相比，治疗后14d两组NIHSS均下降，治疗组优于对照组治疗组（13.60±4.26） vs （9.31±3.79），对照组（13.57±4.20） vs （11.23±4.06），P＝0.045]。与治疗前相比，治疗后14d两组BI差异无统计学意义（P＞0.05）；随访90d时两组BI均明显升高，且治疗组优于对照组治疗组（54.57±24.17） vs （77.86±21.46），对照组（54.14±23.81） vs （67.0±23.30），P＝0.047]。与治疗前相比，治疗后14d两组mRS变化不明显（P＞0.05）；治疗后90d，治疗组mRS较治疗前明显减低，且治疗组优于对照组治疗组（3.40±0.81）vs（2.80±0.96），对照组（3.49±0.82）vs（3.29±0.93），P＝0.035]。两组不良反应发生率相似。结论 NBP注射液可改善急性脑梗死所致的神经功能缺损，改善90d远期预后，安全性良好。

Primary efficacy of DL-3-n-butylphthalide in treatment of acute cerebral infarction

ObjectiveTo evaluate the therapeutic effects of DL-3-n-butylphthalide （NBP） injectionon acute cerebral infarction and its adverse reactions.MethodsSeventy patientswith acute cerebral infarctionadmitted in ourhospitalfrom September 2012 to November 2013were randomly divided into standard treatment plusNBP （n=35） and standard treatment （control,n=35） groups.Before andin14d after the treatment,the degree of neurological deficitwas evaluated byNational Institutes of HealthStrokeScale （NIHSS）, daily living skills assessment were assessedbyBarthel Index（BI） andmodified Rankin Score（mRS）, and adverse reactions were recorded. BI and mRS werealsofollowed upin90d after the treatment.Results In14dafter treatment, NIHSS were decreasedin both NBP and control groups compared with pretreatment. The decreasein NIHSSwas more significant in NBP group thanincontrol groupNBP group：（13.60±4.26）vs （9.31±3.79）; control group：（13.57±4.20）vs（11.23±4.06）;P=0.045]. No obvious changeof BIwasfoundin both 2 groupsin 14 d after treatment. TheBIatthefollow-upof90 dwas significantly higher in NBP group than in control group（NBP group：（54.57±24.17）vs （77.86±21.46）; control group：（54.14±23.81）vs（67.0±23.30）;P=0.047）].There was no significant change inmRSin both2groupsafter treatment for 14d.In 90d after the treatment, the decreasein mRS was more significant in NBP group thanincontrol groupNBP group：（3.40±0.81）vs（2.80±0.96）; control group：（3.49±0.82）vs（3.29±0.93）;P=0.035].The incidenceof adverse reactions wasidentical betweenthe 2 groups.Conclusion NBP injectionobviouslyimproves neurological deficitresulting fromacute cerebral infarction, andalso improves90-day outcome with sound safety.